- Home
- BREA vs NXTC Comparison
BREA vs NXTC Comparison
Compare BREA & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BREA
- NXTC
- Stock Information
- Founded
- BREA 2022
- NXTC 2015
- Country
- BREA Ireland
- NXTC United States
- Employees
- BREA N/A
- NXTC N/A
- Industry
- BREA Services-Misc. Amusement & Recreation
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- BREA Consumer Discretionary
- NXTC Health Care
- Exchange
- BREA Nasdaq
- NXTC Nasdaq
- Market Cap
- BREA 14.8M
- NXTC 12.8M
- IPO Year
- BREA 2023
- NXTC 2019
- Fundamental
- Price
- BREA $6.00
- NXTC $4.94
- Analyst Decision
- BREA
- NXTC Strong Buy
- Analyst Count
- BREA 0
- NXTC 2
- Target Price
- BREA N/A
- NXTC $25.50
- AVG Volume (30 Days)
- BREA 5.4K
- NXTC 19.5K
- Earning Date
- BREA 01-01-0001
- NXTC 08-07-2025
- Dividend Yield
- BREA N/A
- NXTC N/A
- EPS Growth
- BREA N/A
- NXTC N/A
- EPS
- BREA N/A
- NXTC N/A
- Revenue
- BREA $2,988,009.00
- NXTC N/A
- Revenue This Year
- BREA N/A
- NXTC N/A
- Revenue Next Year
- BREA N/A
- NXTC N/A
- P/E Ratio
- BREA N/A
- NXTC N/A
- Revenue Growth
- BREA 151.51
- NXTC N/A
- 52 Week Low
- BREA $5.00
- NXTC $2.69
- 52 Week High
- BREA $19.50
- NXTC $19.20
- Technical
- Relative Strength Index (RSI)
- BREA 42.63
- NXTC 43.79
- Support Level
- BREA $5.71
- NXTC $4.83
- Resistance Level
- BREA $6.56
- NXTC $5.15
- Average True Range (ATR)
- BREA 0.24
- NXTC 0.23
- MACD
- BREA -0.05
- NXTC -0.01
- Stochastic Oscillator
- BREA 27.37
- NXTC 15.44
About BREA Brera Holdings PLC
Brera Holdings PLC focused on expanding social impact football by developing a international portfolio of emerging football clubs with increased opportunities to earn tournament prizes, gain sponsorships, and provide other professional football and related consulting services.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.